Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.

Cancer Sci · 2019 · PMC6676125 · PMID 31218770

Europe PMC DOI

hedged sentence

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

did not reach statistical significanceP = .071so close (0.05 < p ≤ 0.1)

SVN‐2B peptide‐specific tetramer staining was increased after 8 weeks in the SVN‐2B + IFNβ group; however, the difference did not reach statistical significance ( P = .071; Figure 2 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.